Alpha1-antitrypsin gene therapy (Valentis/Vanderbilt）

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlpha1-antitrypsin gene therapy (Valentis/Vanderbilt）
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionTrypsin modulators
TargetsTrypsin
Therapy Area/IndicationsEmphysemaalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesValentisVanderbilt University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesValentisVanderbilt University Medical Center
Active IndicationsN/A
Inactive IndicationsEmphysemaalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A